Immutep's Pivotal Presentation at the European Lung Cancer Congress
SYDNEY, AUSTRALIA — Immutep Limited (ASX: IMM; NASDAQ: IMMP), a prominent late-stage immunotherapy company focused on treating cancer and autoimmune diseases, has announced an exciting opportunity at the upcoming European Lung Cancer Congress (ELCC). The congress, taking place in Paris, promises to be a significant event for medical professionals in the field of lung cancer.
The company will showcase a poster presentation focusing on the pivotal TACTI-004 Phase III trial. This presentation will occur during the congress scheduled from March 26 to March 29. Attendees hungry for knowledge will gain insights into the innovative study and its implications for future lung cancer treatments.
Overview of the TACTI-004 Phase III Trial
The TACTI-004 trial is designed to investigate the effects of Immutep's MHC Class II agonist, eftilagimod alfa (efti), in combination with MSD's (Merck & Co., Inc.) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), and chemotherapy. This promising regimen is aimed at patients facing advanced or metastatic non-small cell lung cancer (1L NSCLC).
Approximately 750 patients from various backgrounds will be enrolled, incorporating diverse PD-L1 expression profiles and tumor types. This global trial will be conducted across over 150 clinical sites in more than 25 countries, showcasing the commitment to understanding and improving treatment outcomes on an international scale.
Engaging with the Oncology Community
Frédéric Triebel, Immutep's Chief Scientific Officer, expressed enthusiasm about engaging with the lung cancer community at the ELCC. He emphasized the potential of combining efti with KEYTRUDA to revolutionize treatment approaches for patients. Triebel highlighted the trial's ongoing recruitment efforts and optimism that the results will support the promising safety and efficacy profiles observed so far.
Details of the Poster Presentation
For those attending the ELCC, the details of the poster presentation are as follows:
- Title: TACTI-004: a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C
- Presentation Number: 131TiP
- Presenter: Margarita Majem, MD, PhD, Hospital de la Santa Creu i Sant Pau
- Session Date and Time: March 26, 2025, at 13:50 CET
After the presentation, the poster will also be accessible on Immutep's website, providing a resource for further insight into the trial.
About Eftilagimod Alfa
Eftilagimod alfa is a groundbreaking immunotherapy developed by Immutep, designed to stimulate both innate and adaptive immunity against cancer. As a first-in-class antigen presenting cell (APC) activator, efti significantly enhances the immune system's capacity to combat malignancies. It achieves this by activating critical immune cells, including CD8+ cytotoxic T cells and CD4+ helper T cells.
The Future of Efti in Cancer Treatment
Currently, efti is under extensive evaluation for several solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and metastatic breast cancer. Its remarkable safety profile allows incorporation with various treatment regimens, particularly anti-PD-[L]1 immunotherapy and chemotherapy. Notably, efti has received Fast Track designation from the FDA for first-line treatment in both HNSCC and NSCLC.
About Immutep
As a pioneer in advancing immunotherapy solutions, Immutep is dedicated to harnessing the power of Lymphocyte Activation Gene-3 (LAG-3) for therapeutic purposes. Their robust product portfolio is focused on enhancing the immune response for the benefit of patients, while consistently striving to deliver innovative treatment options and maximizing shareholder value.
For more in-depth information about Immutep and its initiatives, visit their official website.
Frequently Asked Questions
What is the TACTI-004 trial about?
The TACTI-004 trial aims to evaluate the efficacy of eftilagimod alfa combined with KEYTRUDA and chemotherapy for treating advanced non-small cell lung cancer.
When will the poster presentation take place?
The presentation is scheduled for March 26, 2025, at 13:50 CET during the European Lung Cancer Congress in Paris.
How many patients will be enrolled in the TACTI-004 trial?
Approximately 750 patients will participate in the global trial, regardless of their PD-L1 expression and tumor type.
What is efti and its role in immunotherapy?
Efti is an MHC Class II agonist that enhances the immune system's ability to fight cancer by activating critical immune cells.
What other cancers are being explored for treatment with efti?
Efti is currently being evaluated for non-small cell lung cancer, head and neck squamous cell carcinoma, and metastatic breast cancer, among others.
